


We Claim:

1. A compound of formula I or of tautomeric formula II



wherein:

R_1 and R_5 are each independently H, F, Cl, Br, CH_2F , CHF_2 , CF_3 , Me, or OMe;
 R_2 and R_4 are each independently H, a branched C_{3-6} -alkyl, F, Cl, Br, CH_2F , CHF_2 , CF_3 or Me, wherein at least one of the groups R_2 or R_4 is a branched C_{3-6} -alkyl; and
 R_3 is H, F, Cl, Br, CH_2F , CHF_2 , CF_3 or Me,

or a pharmacologically acceptable salt thereof.

2. The compound according to claim 1, wherein:

R_1 and R_5 are each independently H, F, Cl, Br, CF_3 , Me, or OMe;
 R_2 and R_4 are each independently H, iPr, *tert*-Bu, F, Cl, Br, CF_3 or Me, wherein at least one of the groups R_2 or R_4 is iPr or *tert*-Bu; and
 R_3 is H, F, Cl, Br, CF_3 or Me.

3. The compound according to claim 1, wherein:

R_1 and R_5 are each independently H, F, Cl, Br, CF_3 , Me, or OMe;
 R_2 and R_4 are each independently H, iPr, *tert*-Bu or Me, wherein at least one of the groups R_2 or R_4 is iPr or *tert*-Bu; and
 R_3 is H, F, Cl, Br, or Me.

4. The compound according to claim 1, wherein:

R_1 is H, Cl, Br, or Me;
 R_2 is iPr or *tert*-Bu;

R₃ is H, Br, or Cl;

R₄ is H; and

R₅ is H, Cl, Br, or OMe.

5. The compound according to claim 1, wherein:

R₁ is H or Me;

R₂ is iPr or *tert*-Bu;

R₃ is H, Cl, or Br;

R₄ is H; and

R₅ is H or OMe.

6. The compound according to claim 1, wherein:

R₁ is H, F, Cl, Br, CH₂F, CHF₂, CF₃, or Me;

R₂ is iPr or *tert*-Bu; and

R₄ is H.

7. A compound selected from the group consisting of:

- (a) 3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazolidine **1**;
- (b) 3'-*tert*-butyl-6'-methoxyphen-1'-yl-2-iminoimidazolidine **2**;
- (c) 6'-chloro-3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazolidine **3**;
- (d) 4'-chloro-3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazolidine **4**;
- (e) 6'-bromo-3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazolidine **5**;
- (f) 6'-bromo-3'-*tert*-butylphen-1'-yl-2-iminoimidazolidine **6**; and
- (g) 4'-bromo-3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazolidine **7**.

8. 5'-chloro-3'-isopropyl-2'-methylphen-1'-yl-2-iminoimidazoline **27**.

9. The compound according to claim 1, wherein the compound according to formula I is an iminoimidazolidine.

10. The compound according to claim 1, wherein the compound according to formula II is an aminoimidazoline.

11. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable excipient.

12. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable excipient.

13. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising the compound according to claim 4 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising the compound according to claim 5 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising the compound according to claim 6 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising the compound according to claim 7 and a pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising the compound according to claim 8 and a pharmaceutically acceptable excipient.

19. A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable excipient.

20. A pharmaceutical composition comprising the compound according to claim 10 and a pharmaceutically acceptable excipient.

21. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 1.

22. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 2.

23. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 3.

24. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 4.

25. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 5.

26. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 6.

27. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 7.

28. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 8.

29. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 9.

30. A method of treating urinary incontinence or a bladder disease in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to claim 10.

10058456.012802